1-10 of 10
Mark A. Schroeder
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma

Rachael A. Vaubel, Shulan Tian, Dioval Remonde, Mark A. Schroeder, Ann C. Mladek, Gaspar J. Kitange, Alissa Caron, Thomas M. Kollmeyer, Rebecca Grove, Sen Peng, Brett L. Carlson, Daniel J. Ma, Gobinda Sarkar, Lisa Evers, Paul A. Decker, Huihuang Yan, Harshil D. Dhruv, Michael E. Berens, Qianghu Wang, Bianca M. Marin, Eric W. Klee, Andrea Califano, Daniel H. LaChance, Jeanette E. Eckel-Passow, Roel G. Verhaak, Erik P. Sulman, Terry C. Burns, Fredrick B. Meyer, Brian P. O'Neill, Nhan L. Tran, Caterina Giannini, Robert B. Jenkins, Ian F. Parney, Jann N. Sarkaria
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (5): 1094–1104.
https://doi.org/10.1158/1078-0432.CCR-19-0909
Published: 02 March 2020
View articletitled, Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma
Open the PDF for Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Joseph M. Tuscano, Emanual Maverakis, Susan Groshen, Denice Tsao-Wei, Guillaume Luxardi, Alexander A. Merleev, Anne Beaven, John F. DiPersio, Leslie Popplewell, Robert Chen, Mark Kirschbaum, Mark A. Schroeder, Edward M. Newman
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (23): 7004–7013.
https://doi.org/10.1158/1078-0432.CCR-19-0438
Published: 02 December 2019
View articletitled, A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Open the PDF for A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Mark A. Schroeder, Mark A. Fiala, Eric Huselton, Michael H. Cardone, Savina Jaeger, Sae Rin Jean, Kathryn Shea, Armin Ghobadi, Tanya Wildes, Keith E. Stockerl-Goldstein, Ravi Vij
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (13): 3776–3783.
https://doi.org/10.1158/1078-0432.CCR-18-1909
Published: 01 July 2019
View articletitled, A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Open the PDF for A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma in another window
Journal Articles

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure

Amer M. Zeidan, Hanna A. Knaus, Tara M. Robinson, Andrea M.H. Towlerton, Edus H. Warren, Joshua F. Zeidner, Amanda L. Blackford, Amy S. Duffield, David Rizzieri, Mark G. Frattini, Yair M. Levy, Mark A. Schroeder, Anna Ferguson, Katherine E. Sheldon, Amy E. DeZern, Ivana Gojo, Steven D. Gore, Howard Streicher, Leo Luznik, B. Douglas Smith
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15): 3519–3527.
https://doi.org/10.1158/1078-0432.CCR-17-3763
Published: 31 July 2018
View articletitled, A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Open the PDF for A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

Michael R. Savona, Daniel A. Pollyea, Wendy Stock, Vivian G. Oehler, Mark A. Schroeder, Jeffrey Lancet, James McCloskey, Hagop M. Kantarjian, Weidong Wendy Ma, M. Naveed Shaik, A. Douglas Laird, Mirjana Zeremski, Ashleigh O'Connell, Geoffrey Chan, Jorge E. Cortes
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (10): 2294–2303.
https://doi.org/10.1158/1078-0432.CCR-17-2824
Published: 14 May 2018
View articletitled, Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
Open the PDF for Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS in another window
Includes: Supplementary data
Journal Articles

The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

Jenny L. Pokorny, David Calligaris, Shiv K. Gupta, Dennis O. Iyekegbe, Jr, Dustin Mueller, Katrina K. Bakken, Brett L. Carlson, Mark A. Schroeder, Debra L. Evans, Zhenkun Lou, Paul A. Decker, Jeanette E. Eckel-Passow, Vincenzo Pucci, Bennett Ma, Stuart D. Shumway, William F. Elmquist, Nathalie Y.R. Agar, Jann N. Sarkaria
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (8): 1916–1924.
https://doi.org/10.1158/1078-0432.CCR-14-2588
Published: 14 April 2015
View articletitled, The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
Open the PDF for The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts

Shiv K. Gupta, Ann C. Mladek, Brett L. Carlson, Felix Boakye-Agyeman, Katrina K. Bakken, Sani H. Kizilbash, Mark A. Schroeder, Joel Reid, Jann N. Sarkaria
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (14): 3730–3741.
https://doi.org/10.1158/1078-0432.CCR-13-3446
Published: 14 July 2014
View articletitled, Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts
Open the PDF for Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts in another window
Includes: Supplementary data
Journal Articles

Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts

Gaspar J. Kitange, Ann C. Mladek, Brett L. Carlson, Mark A. Schroeder, Jenny L. Pokorny, Ling Cen, Paul A. Decker, Wenting Wu, Gwen A. Lomberk, Shiv K. Gupta, Raul A. Urrutia, Jann N. Sarkaria
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (15): 4070–4079.
https://doi.org/10.1158/1078-0432.CCR-12-0560
Published: 30 July 2012
View articletitled, Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts
Open the PDF for Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts in another window
Includes: Supplementary data
Journal Articles

PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel

Lin Yang, Michelle J. Clarke, Brett L. Carlson, Ann C. Mladek, Mark A. Schroeder, Paul Decker, Wenting Wu, Gaspar J. Kitange, Patrick T. Grogan, Jennie M. Goble, Joon Uhm, Evanthia Galanis, Caterina Giannini, Heidi A. Lane, C. David James, Jann N. Sarkaria
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3993–4001.
https://doi.org/10.1158/1078-0432.CCR-07-4152
Published: 16 June 2008
View articletitled, PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel
Open the PDF for PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel in another window
Journal Articles

Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response

Jann N. Sarkaria, Brett L. Carlson, Mark A. Schroeder, Patrick Grogan, Paul D. Brown, Caterina Giannini, Karla V. Ballman, Gaspar J. Kitange, Abjahit Guha, Ajay Pandita, C. David James
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (7): 2264–2271.
https://doi.org/10.1158/1078-0432.CCR-05-2510
Published: 11 April 2006
View articletitled, Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response
Open the PDF for Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response in another window